Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03950999
Other study ID # 273/17
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 13, 2017
Est. completion date June 2019

Study information

Verified date May 2019
Source University of Haifa
Contact Roi Treister, PhD
Phone 972-(0)4-6146214
Email treister.roi@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Good clinical care relies on precise evaluation of patients' conditions. Chronic pain and other neurological and psychiatric diagnoses pose challenges because their assessment depends on subjective patient-reported outcome measures (PROs). The investigators have recently developed the Focused Analgesia Selection Task (FAST), a method that allows assessing pain reporting accuracy. Preliminary results suggest that those who more accurately report their pain show diminished placebo response. The underlying mechanisms for this observation cannot be explained by current theories. Therefore, the investigators have conducted a pilot study to further characterize this relation in healthy population.


Description:

Instruments and procedures:

Instruments All stimuli were applied by a contact-heat Thermal Sen-sory Analyzer 2001 system (Medoc, Ramat-Yishai, Israel) with a 30 x 30mm Peltier surface stimulator, which was attached by Velcro straps to the volar surface of the forearm of the subjects' hand.

Familiarization session At the beginning of the experimental session, all subjects underwent short training in order to familiarize them with the device and with the sensations evoked by the painful stimulation, and to train them to report their perceived pain intensity using the numerical pain scale. The training included exposure to three short contact-heat stimuli (44, 46.5, and 48°C), each lasting for 7 seconds from the time that the stimulation intensity reached the destination temperature. The thermode was moved following each stimulus to a completely distinct, adjacent area of skin. Subjects were asked to report the numerical pain score (NPS), on a scale ranging from 0, denoting no pain, to 100, denoting the worst pain imaginable, induced by each stimulus.

Pain reporting accuracy assessment:

The subject's pain reporting accuracy skills was assessed by the FAST, which is based on recording a subject's pain reports in response to repeated administration of thermal noxious stimuli of various intensities. During the FAST procedure the thermode was attached to the ventral surface of the subject's non-dominant arm and the temperature was raised from a baseline of 32°C, peaked for 3 seconds at 1 of 7 designated temperatures (44°C, 45°C, 46°C, 47°C, 48°C, 49°C, and 50°C), and then decreased down to the baseline. Stimulus rate of rise and fall was kept constant at 8°C/seconds. Subjects were asked to rate the peak pain intensity of each stimulus verbally using the NPS. Each temperature was presented 7 times in a random block-ordered design (49 stimuli in total). Inter-stimulus intervals of 20 seconds allowed the subject sufficient time to rate the pain they perceived during each stimulus. The location of the thermode was adjusted every 10 stimuli to minimize sensitization and/or habituation effects. The duration of the FAST procedure is ~25 minutes.

Placebo assessment:

The placebo effect was assessed using tonic heat delivered at fixed temperature of either 44, 46.5, and 48°C. As was shown by previous studies, these temperatures evokes mild, moderate and severe pain sensations. During the stimuli, the thermode was attached to the volar surface of the forearm of the subjects' dominant hand. Baseline temperature was 32.0 °C, with an increasing temperature rate of 2°C/s and a return-to-baseline temperature rate of 8°C/s. Pain intensity ratings of heat stimuli were assessed verbally using NPS, at 2, 10 and 20 sec after the initiation of the stimulus.

Placebo procedure:

Each subject received clinical trial-type instructions before receiving the placebo so that the condition of the study would be similar to those encountered in typical drug trials. Subjects consented to participate in a study examining the analgesic effects of a well-known established pain relief medication. The subjects were told that they were about to receive a pain relief medication, which is commonly used in clinical practice. Possible adverse effects of the substance in question were then described, but it was indicated that the investigators did not typically observe significant adverse effects. Actual pharmacological agents were not administered.

Study design:

All experiments were conducted in the same setting, by the same investigator. The experiment was performed in a quiet room with an ambient temperature of 23°C. After the familiarization stage, the experiment begun with delivery of the FAST. After a 10 min break, subjects received the three tonic heat stimuli, each lasting 20 sec long, in a pseudo-random order with 60 sec break between each stimulus. Thereafter each subject was given a placebo pill. In order to evaluate placebo effect, the tonic heat stimuli were administered 20 minutes after placebo intake maintaining the same stimuli order.

The net placebo effect (Δ) was calculated as the difference between the mean NPS of the mild, moderate, and severe pain stimuli administrated before the placebo (Pre-placebo) minus the same after placebo (Post-placebo). The placebo effect in percent was calculated as the ratio of Post-placebo to Pre-placebo double 100. Positive values indicate efficient placebo effect.

The total duration of the experimental session was approximately 1 hours and 30 minutes.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date June 2019
Est. primary completion date June 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- absence of acute or chronic pain disorders;

- no reports of psychiatric, cognitive and /or neurological disorders;

- no drugs including, analgesics or anti-anxiety medications on regular use (except for oral contraceptives).

Exclusion Criteria:

- pregnant or breast-feeding;

- unable to give informed consent, communicate and understand the purpose and the instructions of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Placebo
Sugar pill

Locations

Country Name City State
Israel University of Haifa, The Clinical Pain Innovation Lab Haifa

Sponsors (1)

Lead Sponsor Collaborator
University of Haifa

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain reporting accuracy Subjects will be asked to report their pain on numerical pain scale (NPS) ranging from 0, denoting "no pain", to 10, denoting "the worst pain imaginable". Fast procedure itself (49 heat stimuli, from 7 designated heat temperatures, given in a random block-order design) lasting approximately 20 minutes.
Primary Change in experimental pain perception due to placebo pill intake Subjects will be asked to report their pain on numerical pain scale (NPS) ranging from 0, denoting "no pain", to 10, denoting "the worst pain imaginable". The placebo effect (?) will be calculated as the difference between the mean NPS. Tonic stimuli before the placebo (Pre-placebo) until receiving the same stimuli 20 minutes after taking the placebo pill (Post-placebo).
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1